Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

General Health

Health

Clinical Trials

Other Health

Gritgen Therapeutics Co., Ltd.

More Like This

Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China (Photo: Business Wire)

Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

PR Newswire associated0

The World's First Clinical Base Edting Therapy for Hemoglobinopathy

PR Newswire associated0

GenSci Launches Global Innovation Hub in Shanghai

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

PR Newswire associated0

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE